The medical devices market continued to generate stellar growth in 2022. With the increasing prevalence of cardiovascular and cerebralvascular disease in China, companies are encouraged to develop and create new innovative solutions. Below, EqualOcean has listed 10 leading interventional medical device companies in vascular or neurology fields with overseas business. We hope this will shed some light on Chinese interventional markets.
Lepu Medical (Chinese: 乐普医疗) was established in 1999. As a professional medical technology group, it specializes in developing, manufacturing and marketing high-tech medical devices and equipment. Today, Lepu Medical has grown into a global leading group company in the fields of cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics and general surgery. In 2009, Lepu Medical successfully went public and listed on Chinext Shenzhen Stock Exchange Market. As for the overseas market, Lepu has sales channels covering 80+ countries and regions, and more than 10 global OEM partners. It obtained local registration in 27 countries, and established 4 overseas group members located in the US, Netherlands, Turkey and India. Now 119 products have received CE certificate and 11 products have got FDA approval.
Founded in 1998, MicroPort (Chinese: 微创医疗) is a global medical devices company in multiple international markets across multiple fields, including orthopedics, cardiovascular intervention, cardiac rhythm management, electro-physiology, endovascular, peripheral vascular intervention, among others. Within two decades, MicroPort has transformed itself from a market follower, into a global leader in the field of Percutaneous Coronary Intervention (PCI). Its proprietary Firehawk targeted eluting stent system, with proven clinical evidence in terms of safety and efficacy, has become a leading stent, setting industry standards for a new generation of global cardiac stents. Its TAVR solution is fast becoming the leading therapeutic solution to treat aortic valve disease within China, and is currently expanding to more markets across the globe.
Founded in 2008, Acotec (Chinese: 先瑞达）is a leading interventional medical device company in China. Its products are mainly used for vascular interventional treatment, including Drug-coated Balloons (DCB) and Percutaneous Transluminal Angioplasty Balloon Catheter (PTA) etc. The PTA Catheter, DCB, Fixed Curve Diagnostic Catheter, and RF Ablation Catheter have passed CFDA approval with PTA and DCB passing CE Certification. AcoArt Orchid & Dhalia, AcoArt Tulip & Litos are Acotec's core products. Acotec created and nurtured the peripheral DCB market in China from scratch, where AcoArt Orchid & Dhalia maintained a 100% market share for over three years since its launch and is still occupying the lion's share in the market to date. With a number of essential intellectual property rights domestic and abroad, Acotec serves clients in China, Asia, Europe and other countries and regions.
Founded in 2002, APT Medical (Chinese: 惠泰医疗) is a leading manufacturer and supplier of EP and Vascular Intervention medical devices, committed to advancing the interventional medical field utilizing technologies and innovations. APT Medical’s growing product portfolio covers Electrophysiology, Cardiology, Peripheral, and Neuro intervention. Main products include Mapping Catheter, Ablation Catheter, Transspetal Needle and Sheath, Balloon Catheter, Hemostasis Introducer, Guidewire, Microcatheter, etc. In 2006, it became the first company in China to receive CFDA certificate for EP catheters. Then several products including Ablation catheter, EP catheters, and coronary intervention have received CFDA certificate or CE in the next few years. In 2021, APT Medical listed on the Shanghai STAR Exchange. In 2022, APT Medical announced the opening of its first overseas subsidiary in Indonesia, which marked its expansion and commitment to the Asian market and further overseas expansion.
Zylox-Tonbridge (Chinese: 归创通桥) is a leading player in the peripheral and neurovascular interventional medical device market in China. With strong R&D and manufacturing capabilities, multiple specialized technology platforms, and proven commercialization capabilities, Zylox-Tonbridge strives to provide the most comprehensive product solutions for peripheral and neurovascular medical devices in China and around the world. Since its establishment in 2012, Zylox-Tonbridge has systematically developed more than 40 quality products to adequately cover the rapidly growing neurovascular and peripheral vascular intervention market. It has obtained NMPA approval for eight important products such as Clot retriever stent (ICR), Aspiration catheter, PTA drug-coated balloon catheter (DCB), and Snare Retrieval Kit for IVC Filter.
WEGO Intervention (Chinese: 威高介入) mainly engaged in the production and operation of interventional devices and consumables. The primary industrial group products cover interventional devices and consumables for coronary interventional therapy, congenital heart disease, cerebrovascular disease, digestive tract and other non-vascular diseases, peripheral vascular diseases and cardiac electrophysiological diseases. Marketed products include cardic stent, balloon, guide wire, heart occluders, filter, non-vascular stents, detachable coil, micro guide wire; central venous catheter, disposable blood pressure transducer and other products. One of the companies in industrial group, Shenzhen Kinhely Bio-Tech, was designated by the 973 Program and developed world first "Cobalt-based alloy drug-eluting Stent System with Titanium-oxygen Film without substrate coating".WEGO also has strategic investments or cooperative programs in multiple countries and regions.
Peijia Medical (Chinese: 沛嘉医疗), established in 2012 and listed on the Main Board of the Hong Kong Stock Exchange in May 2020, focuses on the innovation, R&D and production of high-end medical devices for structural heart and cerebrovascular disease intervention, Peijia Medical covers the entire product pipeline for aortic, mitral and tricuspid valve replacements and surgical instruments and accessories, as well as diseases related to hemorrhage, ischemia and access in the field of cerebrovascular intervention. The Company's three generations of TAVR system have been approved by the National Medical Products Administration of the People’s Republic of China as innovative medical devices. With a global outlook, Peijia Medical has set up innovation centers and R&D centers in the United States, Canada, France and other countries to carry out cutting-edge technology research and product development.
Founded in 2009, JC Medical (Chinese: 杰成医疗) is a high-tech enterprise focusing on the development and manufacture of high-end cardiovascular medical devices. The company's leading project is the development and production of innovative "J-Valve accurate positioning heart valve implantation system" technology. The J·Valve Transcatheter Aortic Valve Replacement (TAVR) system is a minimally invasive surgical technique that does not require thoracotomy or extracorporeal blood circulation. It can greatly reduce the surgical trauma of the patient, shorten the postoperative recovery time, reduce the pain of the patient, and reduce the patient’s pain. Now there are more than 3000 cases in Mainland China, 20 cases in HK, and 10 cases in Taiwan. This system also landed in North Amercia and Canada. In 2022, it was acquired by Genesis MedTech (Chinese: 健适医疗).
Founded in 2008, Taijie Yewei Technology (Chinese: 泰杰伟业) is a national high-techenterprise focusing on the field of neurointerventionalmedical devices. It integrates R&D, production, sales and service to bring solutions to hospitals, departments,doctors and patients, improve the overall medical level of the industry, and solve the worldwide problem ofcerebrovascular diseases. At present, the company has 50 independent intellectual property rights, including 22 invention patents and more than 20 trademarks. TJWY's representative products include neurovascular intervention guidewire, intracranial balloon dilatation catheter,disposable intermediate catheter, expandable coilsystem for embolization, coil system forembolization, disposable embolization umbrella,disposable interventional microcatheter, etc. At the same time, in response to the "One Belt, One Road" initiative, the company's products are also exported to the European Union, Southeast Asian countries, Turkey, Colombia, Brazil, Mexicoand some countries in Africa.
Founded in 2019, Kai MedTech (Chinese: 励楷科技) is focused on providing finished device solutions for neurovascular and vascular diseases while providing OEM manufacturing, development, commercialisation, and distribution. KAI MedTech has established four technology platforms: Catheters, Guidewires, Stents and Balloons. The company offers various finished device designs for either direct distribution or commercialization via OEM. The main products include Sheath, Distal Access Catheter, Introducer Sheath, Guiding Catheter, and Microguidewire. In 2021, it received First Class III Device NMPA Registration. Tarvos Microguidewire and Juewa RX Balloon Dilation Catheter are approved in China in 2023. Kai MedTech is capable of successful overseas business. It operates both in the US, German, and China, builds US R&D center, and conducts clinical studies in the US and China.